FOLH1 and prostate cancer: In this study, we assessed the impact of various clinico-biological factors and 68Ga-PSMA PET/CT findings on the response to 177Lu-PSMA treatment in patients with metastatic castration-resistant prostate cancer who had progressed after at least one line of taxane chemotherapy and NHA.